PHILADELPHIA, January 6, 2017: Biotech publication BioWorld Today released a list of the top biopharmaceutical deals of 2016 and Morgan Lewis served as counsel in three of the year’s top ten largest transactions. The transactions totaled nearly $10 billion and included the following: Acerta Pharma B.V. in its sale to AstraZeneca valued at up to $7 billion (the highest valued deal of 2016); Incyte Corp. in its collaboration with Merus; and Xencor in its agreement with Novartis.
The firm’s life sciences team advises industry leaders on product-related M&A as well as securities-related aspects of public and private mergers, divestitures, and joint ventures. Morgan Lewis lawyers handle transactions of varying sizes, up to more than $50 billion, and of different types, including negotiated-purchases and divestitures, tender offers, proxy contests, restructurings, leveraged buyouts, and going private transactions. The group also represents investment banks and commercial banks, venture capital firms, institutional lenders, independent directors committees, and management groups in M&A matters.
Chambers & Partners and Law360 have recognized the life sciences team on a national level and LMG Life Sciences highly recommended Morgan Lewis in the Mergers and Acquisitions chapter of its 2016 USA guide, naming several of the firm’s partners “Life Sciences Stars.